Alexion Pharmaceuticals Stock News

Alexion (ALXN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Alexion (ALXN) announces plans to increase its 2020 sales guidance by more than $200 million and buy back $3 billion of stock.

Drug developers don't get much cheaper than this.

Alexion’s just-released revision to 2020 revenue guidance suggests continuing top line momentum. Given the strong performance through the pandemic, we believe there is even more room for growth as m

Alexion Pharmaceuticals: More Potential Ahead Despite Upbeat Guidance

Announcements that Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) made at its virtual Investor Day about expanding its pipeline and its guidance led to a handy gain in its shares on Tuesday.

Alexion Pharmaceuticals, citing a 'robust pipeline' across seven rare disease franchises, said ahead of its Virtual Investor Day that it expects to hike its sales guidance; ALXN stock rose. The post A

Shares of Alexion Pharmaceuticals Inc. ALXN, +3.31% rose 1.5% in premarket trading Tuesday, after the biopharmaceutical company said it expects to raise its 2020 revenue guidance by more than $200 mil

BOSTON--(BUSINESS WIRE)--Alexion Highlights Promising Pipeline & Distinguished Rare Disease Capabilities at Virtual Investor Day

Their addressable markets may be small, but that doesn't mean developers will fail to profit from these boundary-breaking drugs.

These drugmakers have cornered the markets they need in order to flourish in the long term.

Alexion's (ALXN) Ultomiris gets approval in Japan for the treatment of adults and children living with atypical hemolytic uremic syndrome.

The short interest data are out for September 15, the most recent settlement date.

Alexion (ALXN) gets a positive opinion from the CHMP recommending marketing authorization for a new 100 mg/mL intravenous advanced formulation of Ultomiris in the EU.

This coming weak is likely to be bearish but is also likely to be the end of the September decline.